Stockscreener 앱 받기
227.68
0.30%
0.67
시간 외 거래:
226.58
-1.10
-0.48%
전일 마감가:
$227.01
열려 있는:
$226.05
하루 거래량:
5.30M
Relative Volume:
0.81
시가총액:
$402.58B
수익:
$61.16B
순이익/손실:
$4.19B
주가수익비율:
96.42
EPS:
2.3614
순현금흐름:
$17.82B
1주 성능:
-3.60%
1개월 성능:
+3.07%
6개월 성능:
+3.39%
1년 성능:
+6.60%
1일 변동 폭
$225.29
$229.29
1주일 범위
$223.23
$234.80
52주 변동 폭
$164.39
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
227.68 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
LLY
Lilly Eli Co
|
999.84 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.99 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
AZN
Astrazeneca Plc
|
193.31 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.80 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie’s ABBV-295 Obesity Data Sparks Fresh Interest In Valuation - simplywall.st
UCB's Bimzelx Outperforms AbbVie's Skyrizi in Psoriatic Arthritis Trial - GuruFocus
AbbVie’s Skyrizi beaten by UCB’s Bimzelx in psoriatic arthritis - Seeking Alpha
SageView Advisory Group LLC Buys 13,883 Shares of AbbVie Inc. $ABBV - MarketBeat
Kepler Cheuvreux Suisse SA Takes $7.54 Million Position in AbbVie Inc. $ABBV - MarketBeat
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV) - The Globe and Mail
Franklin Resources Inc. Trims Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital World Investors Sells 139,297 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) gets downgraded to peer perform from outperform by Wolfe Research - MSN
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial - TechStock²
AbbVie’s GLP-1 challenger posts strong weight-loss results in early trial - Crain's Chicago Business
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Delcath Systems (DCTH) - The Globe and Mail
AbbVie Posts Encouraging Early-Stage Data For Amylin Analog ABBV-295 - Citeline News & Insights
Richard Bernstein Advisors LLC Lowers Holdings in AbbVie Inc. $ABBV - MarketBeat
Capital International Investors Has $2.48 Billion Stake in AbbVie Inc. $ABBV - MarketBeat
Legal & General Group Plc Has $2.78 Billion Holdings in AbbVie Inc. $ABBV - MarketBeat
Bank of Montreal Can Raises Stock Position in AbbVie Inc. $ABBV - MarketBeat
William Blair and BMO Maintain Outperform on AbbVie Inc. (ABBV) March 2026 - Meyka
AbbVie reports ‘positive’ results from Phase 1 study of ABBV-295 - TipRanks
AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 millionSEC filing - marketscreener.com
AbbVie (NYSE:ABBV) Shares Down 1% Following Insider Selling - MarketBeat
ICER to review AbbVie’s Parkinson’s disease drug - The Pharma Letter
AbbVie (ABBV) Reports Promising Phase 1 Results for Obesity Trea - GuruFocus
AbbVie's Early Obesity Drug Data Shows Up To 10% Weight Loss - Benzinga
AbbVie sees promising early-stage data for weight loss asset ABBV-295 - Seeking Alpha
AbbVie Trial Updates Add Context To Valuation And Growth Outlook - Yahoo Finance
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Sienna Gestion Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
AbbVie (ABBV) Reports Promising Results from Phase 1 Study of AB - GuruFocus
Gubra's partner AbbVie reports positive phase 1 results for ABBV-295 - marketscreener.com
AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog - TradingView
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults - Yahoo Finance
AbbVie Inc. $ABBV Shares Acquired by LGT Group Foundation - MarketBeat
Jefferies Financial Group Inc. Sells 53,123 Shares of AbbVie Inc. $ABBV - MarketBeat
Streptococcus Market Is Going to Boom | AbbVie • Pfizer • Merck & Co. • GlaxoSmithKline - openPR.com
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s Disease - Insider Monkey
AbbVie Inc. (ABBV) is Drawing Interest from Investors: Key Information You Need to Know - Bitget
AbbVie Inc. $ABBV Shares Bought by Rhenman & Partners Asset Management AB - MarketBeat
AbbVie Stock Analysis: Performance, Financials, and OutlookNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Blair William & Co. IL Has $292.57 Million Position in AbbVie Inc. $ABBV - MarketBeat
Is AbbVie (ABBV) Still Priced Attractively After Its Strong Multi Year Share Price Run - Yahoo Finance
AbbVie (NYSE:ABBV) SVP David Ryan Purdue Sells 5,230 Shares - MarketBeat
Evercore notes AbbVie Inc.’s (ABBV) Tremfya gains market share, but future earnings growth may be limited - MSN
AbbVie (ABBV): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
AbbVie (ABBV) Up 6.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
These 3 Cash Flow Machines Provide Stability in Uncertain Markets - Investing.com
Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026? - Yahoo Finance
Edgar Lomax Co. VA Reduces Stock Position in AbbVie Inc. $ABBV - MarketBeat
Crossmark Global Holdings Inc. Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Berry Wealth Group LP Lowers Stake in AbbVie Inc. $ABBV - MarketBeat
Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative? - Yahoo Finance
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.59%
자본화:
|
볼륨(24시간):